Its technology is based on recombinant human PH20, a human synthetic version of hyaluronidase that degrades hyaluronic acid, which is a major component of skin and cartilage tissues.
Halozyme’s product offerings comprise Cumulase, Enhanze SC, and Chemophase.
Cumulase is an ex vivo formulation of recombinant human PH20 to replace the bovine and ovine enzymes used for the preparation of oocytes prior to in-vitro fertilization and cryopreservation during the process of intracytoplasmic sperm injection, in which the enzyme is an essential component.
Its Enhanze SC is a low unit local formulation of rHuPH20 to replace Wydase.
Enhanze SC also facilitates the penetration and dispersion of other drugs by temporarily opening flow channels under the skin.
Chemophase, a chemoadjuvant, designed to enhance the transport of chemotherapeutic agents to tumor tissue without affecting vascular permeability.
It is used for use in treatment of patients with solid tumor malignancies.
Halozyme has collaborations with Schering-Plough Research Institute and Ludwig Boltzmann Institute of Clinical Oncology.
The company is based in San Diego, California.
